[go: up one dir, main page]

WO1996041813A3 - Polymeres fonctionnalises destines a une ligation dirigee - Google Patents

Polymeres fonctionnalises destines a une ligation dirigee Download PDF

Info

Publication number
WO1996041813A3
WO1996041813A3 PCT/IB1995/001175 IB9501175W WO9641813A3 WO 1996041813 A3 WO1996041813 A3 WO 1996041813A3 IB 9501175 W IB9501175 W IB 9501175W WO 9641813 A3 WO9641813 A3 WO 9641813A3
Authority
WO
WIPO (PCT)
Prior art keywords
functionalized
site
family
topology
aldehyde
Prior art date
Application number
PCT/IB1995/001175
Other languages
English (en)
Other versions
WO1996041813A9 (fr
WO1996041813A2 (fr
Inventor
Robin E Offord
Hubert F Gaertner
Original Assignee
Robin E Offord
Hubert F Gaertner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robin E Offord, Hubert F Gaertner filed Critical Robin E Offord
Priority to EP95944855A priority Critical patent/EP0788375A2/fr
Priority to JP8535165A priority patent/JPH10509208A/ja
Priority to AU73272/96A priority patent/AU7327296A/en
Publication of WO1996041813A2 publication Critical patent/WO1996041813A2/fr
Publication of WO1996041813A3 publication Critical patent/WO1996041813A3/fr
Publication of WO1996041813A9 publication Critical patent/WO1996041813A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

On décrit des polymères organiques, par exemple un poly(éthylène glycol), fonctionnalisé à l'aide d'un groupe amino-oxy formant une oxime, ainsi que des procédés de préparation et d'utilisation de ceux-ci dans une ligation chimiosélective, dirigée, avec une macromolécule cible, ou une surface, fonctionnalisée par un aldéhyde (ou une cétone), dans des conditions de ligation modérées. On décrit également des structures polymères de recombinaison, lesquelles contiennent des multi-polymères, sont fonctionnalisés par amino-oxy ou par un aldéhyde (ou une cétone), et permettent une ligation chimiosélective dirigée, dans des conditions modérées, de la structure de recombinaison (et, ainsi, de tous les polymères de celle-ci) avec un seul site d'une macromolécule cible, via une liaison oxime. On décrit encore des familles de structures de polymères de recombinaison fonctionnalisés, dans lesquelles chaque structure diffère de celles de la même famille quant à sa topologie mais non quant à son poids moléculaire (moyen). Des procédés d'utilisation de ces polymères comprennent la modification systématique d'une macromolécule cible, afin de créer rapidement une famille de molécules cibles, de préférence des protéines biologiquement importantes, différant quant à leur topologie mais non quant à leur poids moléculaire, famille à partir de laquelle on peut identifier des macromolécules possédant les propriétés biologiques ou physiques souhaitées, telles qu'un meilleur comportement pharmacocinétique.
PCT/IB1995/001175 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee WO1996041813A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95944855A EP0788375A2 (fr) 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee
JP8535165A JPH10509208A (ja) 1994-11-09 1995-11-09 部位特異的結合のための官能化されたポリマー
AU73272/96A AU7327296A (en) 1994-11-09 1996-11-09 Functionalized polymers for site-specific attachment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33685094A 1994-11-09 1994-11-09
US08/336,850 1994-11-09
US39469095A 1995-02-23 1995-02-23
US08/394,690 1995-02-23

Publications (3)

Publication Number Publication Date
WO1996041813A2 WO1996041813A2 (fr) 1996-12-27
WO1996041813A3 true WO1996041813A3 (fr) 1997-05-22
WO1996041813A9 WO1996041813A9 (fr) 1997-06-19

Family

ID=26990408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/001175 WO1996041813A2 (fr) 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee

Country Status (4)

Country Link
EP (1) EP0788375A2 (fr)
AU (1) AU7327296A (fr)
CA (1) CA2204726A1 (fr)
WO (1) WO1996041813A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US7351855B2 (en) 1992-07-15 2008-04-01 La Jolla Pharmaceutical Company Chemically defined non-polymeric valency platform molecules and conjugates thereof
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8058433B2 (en) 2000-03-30 2011-11-15 Abbott Laboratories Crystalline pharmaceutical
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525955D0 (en) * 1995-12-19 1996-02-21 Therexsys Ltd Improved pharmaceutical compositions
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
JP4247846B2 (ja) 1997-07-03 2009-04-02 デュピュイ・スパイン・インコーポレーテッド 架橋ポリサッカリド薬物キャリア
FI980489A7 (fi) * 1998-03-04 1999-09-05 Alexei Radievich Khomutov Syklodekstriinien uudet johdannaiset
JP4593048B2 (ja) 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
ES2327606T3 (es) 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
WO2001058935A2 (fr) 2000-02-11 2001-08-16 Maxygen Aps MOLECULES DE TYPE FACTEUR VII OU VIIa
HK1056113A1 (zh) * 2000-06-30 2004-02-06 Smithkline Beecham Corporation 趋化因子共轭物
WO2002019963A2 (fr) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Protéines de synthèse stimulant l'érythropoïèse
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AR030631A1 (es) * 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
WO2002043770A2 (fr) * 2000-12-01 2002-06-06 Conforma Therapeutic Corporation Multimeres de peptides d'accueil, preparation et utilisations associees
MXPA03005406A (es) 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
US9139607B2 (en) * 2002-12-26 2015-09-22 Sumitomo Bakelite Co., Ltd. Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure
SI1596887T1 (sl) 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
US20040249119A1 (en) * 2003-06-05 2004-12-09 Fox Martin Edward Novel mPEG propionaldehyde precursor
EP1653991A2 (fr) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugues de polymere et de proteine lies au moyen d'un groupe de liaison oxime
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1673387B1 (fr) 2003-10-10 2010-09-15 Novo Nordisk A/S Derives de il-21
EP2633866A3 (fr) 2003-10-17 2013-12-18 Novo Nordisk A/S Thérapie combinée
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
SI2363414T1 (sl) 2004-11-12 2022-09-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
SG161209A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP1828224B1 (fr) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
CA2609205A1 (fr) 2005-06-03 2006-12-14 Ambrx, Inc. Molecules d'interferons humains ameliorees et utilisations de celles-ci
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
EP1937824B1 (fr) 2005-08-18 2013-03-13 Ambrx, Inc. COMPOSITIONS D ARNt ET LEURS UTILISATIONS
SI1954710T1 (sl) * 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
US20090018029A1 (en) 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
SG10201405661QA (en) 2005-12-14 2014-10-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
AU2007271150A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
MX2009002526A (es) 2006-09-08 2009-04-16 Ambrx Inc Transcripcion de tarn supresor en celulas de vertebrados.
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CA2663083A1 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations
WO2008049920A2 (fr) 2006-10-26 2008-05-02 Novo Nordisk A/S Variantes il-21
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
WO2008074032A1 (fr) 2006-12-15 2008-06-19 Baxter International Inc. Conjugué du facteur viia et de l'acide (poly)sialique présentant une demi-vie in vivo prolongée
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
CA2685596A1 (fr) 2007-05-02 2008-11-13 Ambrx, Inc. Polypeptides d'interferon beta modifies et leurs utilisations
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2275202A1 (fr) * 2008-03-13 2011-01-19 Ajinomoto Co., Inc. Substance d'élimination de composé carbonyle
EP2318029B1 (fr) 2008-07-23 2017-11-01 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
NZ592250A (en) 2008-09-26 2012-11-30 Lilly Co Eli Modified animal erythropoietin polypeptides and their uses
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
HUE030373T2 (en) * 2009-03-20 2017-05-29 Hanmi Science Co Ltd A method for producing a site-specific conjugate of a physiologically active polypeptide
US8067526B2 (en) 2009-03-27 2011-11-29 Nof Corporation Method for producing polyoxalkylene derivative
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (fr) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation de protéines autres que des protéines de coagulation sanguine
MX2012001207A (es) 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
WO2011107591A1 (fr) 2010-03-05 2011-09-09 Rigshospitalet Molécules chimériques inhibitrices d'activation du complément
EP2569331A1 (fr) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptides inhibiteurs de vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (hu) 2010-08-17 2021-12-28 Ambrx Inc Módosított relaxin polipeptidek és felhasználásuk
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US8409526B2 (en) 2010-12-09 2013-04-02 General Electric Company Cellulose substrates, compositions and methods for storage and analysis of biological materials
MX345608B (es) 2010-12-22 2017-02-07 Baxalta Inc Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
KR102172897B1 (ko) 2012-06-08 2020-11-02 서트로 바이오파마, 인크. 부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
DK2859013T3 (en) * 2012-06-12 2016-12-19 Fina Biosolutions Llc DIFFERENTIAL functionalization of polymers having AMINO-OXY reagents for diagnostic assays
EP3135690A1 (fr) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Proteines fc modifiees contenant des residus specifiques d'acides amines non naturels, leurs conjugues, leurs procedes de preparation et leurs procedes d'utilisation
DK3584255T3 (da) 2012-08-31 2022-04-04 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
EP3019522B1 (fr) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
EP3055298B1 (fr) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
CN106536560B (zh) * 2014-05-23 2021-03-09 诺华股份有限公司 从含二硫化物的蛋白质制备缀合物的方法
CA3052639A1 (fr) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Polypeptides de relaxine modifies comprenant un activateur pharmacocinetique et leurs utilisations
EP3849614B1 (fr) 2018-09-11 2023-12-20 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs utilisations
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN119455004A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
EP4117732A1 (fr) 2020-03-11 2023-01-18 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs procédés d'utilisation
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539167A2 (fr) * 1991-10-21 1993-04-28 Ortho Pharmaceutical Corporation Imidates de PEG et leurs dérivés protéiniques
EP0605963A2 (fr) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Réactifs pour la formation de liaisons de peg-hydrazone et peg-oxime et leurs dérives de protein
WO1994025071A1 (fr) * 1993-05-05 1994-11-10 Keith Rose Composes de polyoximes et leur preparation
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539167A2 (fr) * 1991-10-21 1993-04-28 Ortho Pharmaceutical Corporation Imidates de PEG et leurs dérivés protéiniques
EP0605963A2 (fr) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Réactifs pour la formation de liaisons de peg-hydrazone et peg-oxime et leurs dérives de protein
WO1994025071A1 (fr) * 1993-05-05 1994-11-10 Keith Rose Composes de polyoximes et leur preparation
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VILASECA L ET AL: "PROTEIN CONJUGATES OF DEFINED STRUCTURE: SYNTHESIS AND USE OF A NEW CARRIER MOLECULE", BIOCONJUGATE CHEMISTRY, vol. 4, no. 6, 1 November 1993 (1993-11-01), pages 515 - 520, XP000417288 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351855B2 (en) 1992-07-15 2008-04-01 La Jolla Pharmaceutical Company Chemically defined non-polymeric valency platform molecules and conjugates thereof
US8058433B2 (en) 2000-03-30 2011-11-15 Abbott Laboratories Crystalline pharmaceutical
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Also Published As

Publication number Publication date
AU7327296A (en) 1997-01-09
EP0788375A3 (fr) 1997-09-17
EP0788375A2 (fr) 1997-08-13
CA2204726A1 (fr) 1996-12-27
WO1996041813A2 (fr) 1996-12-27

Similar Documents

Publication Publication Date Title
WO1996041813A3 (fr) Polymeres fonctionnalises destines a une ligation dirigee
WO2003047518A3 (fr) Polymere amphiphile biocompatible greffe avec de la cyclodextrine et methodes de production et d'utilisation
WO2001002017A3 (fr) Derives de l'erythropoietine
DE60213380D1 (de) Kontinuierliches verfahren zur herstellung von engeren molekulargewichtverteilungen konjugierten dien-polymeren und dadurch hergestellten produkten
WO2001032146A3 (fr) Vesicules polymeres amphiphiles
WO2005061005A3 (fr) Echafaudages moleculaires ramifies destines a lier des residus polymeres a des groupes fonctionnels biologiquement actifs
AU6279900A (en) Polymer blends with improved impact resistance
DE60229955D1 (de) Zusammensetzungen, welche stäbchenförmige polymere und nanoröhrenförmige strukturen umfassen, sowie verfahren zur herstellung derselben
CA2315034A1 (fr) Materiau polymere contenant n, p, s, as ou se et composition de materiau de transfert de charge
DE69312700D1 (de) Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
EP1947145A3 (fr) Mélanges de polyesters biodégradables et produits fabriqués à partir de ceux-ci
WO1999003516A3 (fr) Reticulats polymeres semi-interpenetrants
NO954434L (no) Bioaktive og/eller målsökende dendrimer-konjugater
Hachaichi et al. Effect of alkali surface treatment and compatibilizer agent on tensile and morphological properties of date palm fibers‐based high density polyethylene biocomposites
ATE290564T1 (de) Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung
ATE455831T1 (de) Verbesserte polyolefinbasierende klebharze und verfahren zur herstellung von klebharzen
Kim et al. UV-induced graft copolymerization of monoacrylate-poly (ethylene glycol) onto poly (3-hydroxyoctanoate) to reduce protein adsorption and platelet adhesion
ATE340197T1 (de) Hydrogele und verfahren zur herstellung davon
WO1999054349A3 (fr) Molecules d'acides nucleiques dermatophagoides, proteines et leurs utilisations
CA2333379A1 (fr) Polymere contenant du lactide et materiau medical
AU2002215854A1 (en) Method for producing meltable polyesters
EP1236747A4 (fr) Caoutchouc effile aromatique-vinyle/diene-conjugue copolymere, procede de fabrication et composition de caoutchouc
DE60238816D1 (de) Prozess zur herstellung von isobutylenpolymeren mit hohem molekulargewicht
DE59903922D1 (de) Asa-formmassen zur herstellung matter formteile
WO2001009204A3 (fr) Polymeres a architecture controlee et leur utilisation en tant que milieu de separation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2204726

Country of ref document: CA

Ref country code: CA

Ref document number: 2204726

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1995944855

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THERECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1995944855

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995944855

Country of ref document: EP